Gilead Sciences (GILD) just wrapped FY 2025 with fourth quarter revenue of US$7.9b and basic EPS of US$1.76, supported by trailing twelve month revenue of US$29.4b and EPS of US$6.84. Over recent quarters, revenue has moved from US$6.7b in Q1 2025 to US$7.1b in Q2 and US$7.8b in Q3, while quarterly EPS shifted from US$1.06 to US$1.57, US$2.46 and then US$1.76, setting up a year where stronger net profit margins and higher full year earnings put profitability in clear focus for investors.

See our full analysis for Gilead Sciences.

With the headline figures on the table, the next step is to weigh these margins and growth rates against the main narratives around Gilead, to see which stories the numbers support and which they call into question.

28.9% margin and very large earnings jump

• Over the last 12 months, Gilead earned US$8.5b in net income on US$29.4b of revenue, which works out to a 28.9% net profit margin and very large year on year earnings growth described at about 1,673%.
• Bulls point to this profitability as a foundation for future growth, and the recent results give them some numbers to work with.
  • Bulls highlight that strong cash generation from HIV and liver portfolios can support long term margin expansion, and the current 28.9% margin is consistent with that argument.
  • They also lean on the idea of higher margin oncology and cell therapy products supporting earnings over time, and the jump from 1.7% to 28.9% margin shows how sensitive overall profits are when new products and pricing mix come through.

Over 12 months of results like this, some investors will want to see whether the bullish view on future therapies and margins is really backed up by the current profit base, and how much of that very large earnings growth feels repeatable in later years. 🐂 Gilead Sciences Bull Case

P/E of 19.6x and DCF fair value tension

• The stock trades on a trailing P/E of 19.6x, which is below the 40.9x peer average but above the 17.8x US biotech industry average, and the current price of US$134.06 sits far below the cited DCF fair value of about US$288.40.
• Consensus narrative talks about steady but not explosive forecast growth, and the valuation numbers cut both ways against that backdrop.
  • On one hand, earnings are expected to grow about 8.6% per year with revenue at roughly 5.2% per year, and a DCF fair value around US$288.40 suggests the current price is materially below that modelled outcome.
  • On the other hand, the same narrative notes that the stock trades slightly richer than the biotech industry on P/E, so investors weighing the 2.45% dividend and earnings growth will need to decide how much weight to give the DCF gap versus the industry premium.

Debt load and slower forecast growth worries

• Analysis flags a high level of debt alongside forecast revenue growth of about 5.2% per year and earnings growth of roughly 8.6% per year, both described as slower than the broader US market references in the data.
• Bears focus on this combination of leverage and moderate growth assumptions, and the reported numbers give some support to that cautious stance.
  • Bears argue that pricing pressure in HIV and competition in oncology and cell therapy could cap top line momentum, and the 5.2% revenue growth forecast aligns with that more muted view.
  • They also point out that if growth is only in the mid single to high single digit range, a high debt load leaves less room for error if any of the new product launches or reimbursement decisions fall short of expectations.

Skeptical investors will probably keep a close eye on how that debt position trends relative to the mid single digit revenue growth that is being discussed in forecasts. 🐻 Gilead Sciences Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Gilead Sciences on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Curious whether this mix of strong margins, debt concerns and valuation tension feels compelling or concerning for you personally? Act while the details are fresh and test the story against your own expectations using our breakdown of 4 key rewards and 1 important warning sign

See What Else Is Out There

Gilead pairs a high debt load with forecast revenue and earnings growth that is described as slower than broader US market references in the data.

If that mix of leverage and moderate growth gives you pause, you can quickly compare it with companies in the 72 resilient stocks with low risk scores that aim to keep risk in tighter check.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.